Which has better earnings and valuation, MLTX or CMPX?

Compass Therapeutics is trading at a lower price-to-earnings ratio than MoonLake Immunotherapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MoonLake Immunotherapeutics N/A N/A -$227.32M -$3.87 N/A Compass Therapeutics N/A N/A -$66.49M -$0.40 N/A

Is MLTX or CMPX more profitable?

Compass Therapeutics' return on equity of -38.71% beat MoonLake Immunotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets MoonLake Immunotherapeutics N/A -85.15% -60.52% Compass Therapeutics N/A -38.71% -34.72%

Does the media favor CMPX or ALVO?

In the previous week, Compass Therapeutics had 14 more articles in the media than Alvotech. MarketBeat recorded 16 mentions for Compass Therapeutics and 2 mentions for Alvotech. Alvotech's average media sentiment score of 1.16 beat Compass Therapeutics' score of 0.05 indicating that Alvotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Compass Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Alvotech 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ABSI or CMPX?

In the previous week, Compass Therapeutics had 14 more articles in the media than Absci. MarketBeat recorded 16 mentions for Compass Therapeutics and 2 mentions for Absci. Compass Therapeutics' average media sentiment score of 0.05 beat Absci's score of 0.00 indicating that Compass Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Absci 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Compass Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor CMPX or MNKD?

In the previous week, MannKind had 2 more articles in the media than Compass Therapeutics. MarketBeat recorded 18 mentions for MannKind and 16 mentions for Compass Therapeutics. MannKind's average media sentiment score of 0.30 beat Compass Therapeutics' score of 0.05 indicating that MannKind is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Compass Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral MannKind 5 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Is INBX or CMPX more profitable?

Compass Therapeutics' return on equity of -38.71% beat Inhibrx Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Inhibrx Biosciences N/A -563.90% -72.32% Compass Therapeutics N/A -38.71% -34.72%

Does the media prefer INBX or CMPX?

In the previous week, Compass Therapeutics had 14 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 16 mentions for Compass Therapeutics and 2 mentions for Inhibrx Biosciences. Inhibrx Biosciences' average media sentiment score of 0.30 beat Compass Therapeutics' score of 0.05 indicating that Inhibrx Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inhibrx Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Compass Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Compass Therapeutics (CMPX) Competitors

$2.17 +0.03 (+1.16%)

As of 09:59 AM Eastern

Compare

CMPX vs. MLTX, ALVO, ABSI, MNKD, and INBX

Should you buy Compass Therapeutics stock or one of its competitors? MarketBeat compares Compass Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Compass Therapeutics include MoonLake Immunotherapeutics (MLTX), Alvotech (ALVO), Absci (ABSI), MannKind (MNKD), and Inhibrx Biosciences (INBX). These companies are all part of the "biotechnology" industry.

How does Compass Therapeutics compare to MoonLake Immunotherapeutics?

MoonLake Immunotherapeutics (NASDAQ:MLTX) and Compass Therapeutics (NASDAQ:CMPX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, dividends, institutional ownership and analyst recommendations.

MoonLake Immunotherapeutics currently has a consensus price target of $24.21, suggesting a potential upside of 40.76%. Compass Therapeutics has a consensus price target of $11.77, suggesting a potential upside of 441.11%. Given Compass Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Compass Therapeutics is more favorable than MoonLake Immunotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.41
Compass Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88

Compass Therapeutics' return on equity of -38.71% beat MoonLake Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MoonLake Immunotherapeutics	N/A	-85.15%	-60.52%
Compass Therapeutics	N/A	-38.71%	-34.72%

Compass Therapeutics is trading at a lower price-to-earnings ratio than MoonLake Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.87	N/A
Compass Therapeutics	N/A	N/A	-$66.49M	-$0.40	N/A

MoonLake Immunotherapeutics has a beta of 1.06, suggesting that its stock price is 6% more volatile than the broader market. Comparatively, Compass Therapeutics has a beta of 0.92, suggesting that its stock price is 8% less volatile than the broader market.

In the previous week, Compass Therapeutics had 4 more articles in the media than MoonLake Immunotherapeutics. MarketBeat recorded 16 mentions for Compass Therapeutics and 12 mentions for MoonLake Immunotherapeutics. MoonLake Immunotherapeutics' average media sentiment score of 0.59 beat Compass Therapeutics' score of 0.05 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MoonLake Immunotherapeutics	6 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Compass Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

93.8% of MoonLake Immunotherapeutics shares are owned by institutional investors. Comparatively, 68.4% of Compass Therapeutics shares are owned by institutional investors. 10.4% of MoonLake Immunotherapeutics shares are owned by insiders. Comparatively, 18.7% of Compass Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Compass Therapeutics beats MoonLake Immunotherapeutics on 10 of the 14 factors compared between the two stocks.

How does Compass Therapeutics compare to Alvotech?

Compass Therapeutics (NASDAQ:CMPX) and Alvotech (NASDAQ:ALVO) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability, media sentiment and earnings.

Compass Therapeutics has a net margin of 0.00% compared to Alvotech's net margin of -14.36%. Alvotech's return on equity of -11.92% beat Compass Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compass Therapeutics	N/A	-38.71%	-34.72%
Alvotech	-14.36%	-11.92%	-7.59%

Compass Therapeutics currently has a consensus price target of $11.77, indicating a potential upside of 441.11%. Alvotech has a consensus price target of $7.60, indicating a potential upside of 103.21%. Given Compass Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Compass Therapeutics is more favorable than Alvotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compass Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88
Alvotech	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

68.4% of Compass Therapeutics shares are owned by institutional investors. 18.7% of Compass Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Compass Therapeutics had 14 more articles in the media than Alvotech. MarketBeat recorded 16 mentions for Compass Therapeutics and 2 mentions for Alvotech. Alvotech's average media sentiment score of 1.16 beat Compass Therapeutics' score of 0.05 indicating that Alvotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Compass Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alvotech	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alvotech has higher revenue and earnings than Compass Therapeutics. Alvotech is trading at a lower price-to-earnings ratio than Compass Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compass Therapeutics	N/A	N/A	-$66.49M	-$0.40	N/A
Alvotech	$588.90M	1.92	$27.92M	-$0.25	N/A

Compass Therapeutics has a beta of 0.92, indicating that its share price is 8% less volatile than the broader market. Comparatively, Alvotech has a beta of 0.18, indicating that its share price is 82% less volatile than the broader market.

Summary

Compass Therapeutics beats Alvotech on 10 of the 16 factors compared between the two stocks.

How does Compass Therapeutics compare to Absci?

Absci (NASDAQ:ABSI) and Compass Therapeutics (NASDAQ:CMPX) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.

Compass Therapeutics has a net margin of 0.00% compared to Absci's net margin of -6,450.76%. Compass Therapeutics' return on equity of -38.71% beat Absci's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Absci	-6,450.76%	-66.32%	-57.01%
Compass Therapeutics	N/A	-38.71%	-34.72%

In the previous week, Compass Therapeutics had 14 more articles in the media than Absci. MarketBeat recorded 16 mentions for Compass Therapeutics and 2 mentions for Absci. Compass Therapeutics' average media sentiment score of 0.05 beat Absci's score of 0.00 indicating that Compass Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Absci	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Compass Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Compass Therapeutics has lower revenue, but higher earnings than Absci. Absci is trading at a lower price-to-earnings ratio than Compass Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Absci	$2.80M	525.66	-$115.18M	-$0.83	N/A
Compass Therapeutics	N/A	N/A	-$66.49M	-$0.40	N/A

52.1% of Absci shares are held by institutional investors. Comparatively, 68.4% of Compass Therapeutics shares are held by institutional investors. 10.5% of Absci shares are held by insiders. Comparatively, 18.7% of Compass Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Absci has a beta of 2.35, suggesting that its share price is 135% more volatile than the broader market. Comparatively, Compass Therapeutics has a beta of 0.92, suggesting that its share price is 8% less volatile than the broader market.

Absci currently has a consensus target price of $13.43, indicating a potential upside of 42.24%. Compass Therapeutics has a consensus target price of $11.77, indicating a potential upside of 441.11%. Given Compass Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Compass Therapeutics is more favorable than Absci.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Absci	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78
Compass Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88

Summary

Compass Therapeutics beats Absci on 14 of the 16 factors compared between the two stocks.

How does Compass Therapeutics compare to MannKind?

Compass Therapeutics (NASDAQ:CMPX) and MannKind (NASDAQ:MNKD) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings, profitability and media sentiment.

Compass Therapeutics presently has a consensus target price of $11.77, indicating a potential upside of 441.11%. MannKind has a consensus target price of $9.22, indicating a potential upside of 127.34%. Given Compass Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Compass Therapeutics is more favorable than MannKind.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compass Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88
MannKind	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

Compass Therapeutics has a net margin of 0.00% compared to MannKind's net margin of -11.08%. MannKind's return on equity of -11.21% beat Compass Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compass Therapeutics	N/A	-38.71%	-34.72%
MannKind	-11.08%	-11.21%	-6.31%

In the previous week, MannKind had 2 more articles in the media than Compass Therapeutics. MarketBeat recorded 18 mentions for MannKind and 16 mentions for Compass Therapeutics. MannKind's average media sentiment score of 0.30 beat Compass Therapeutics' score of 0.05 indicating that MannKind is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Compass Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
MannKind	5 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

MannKind has higher revenue and earnings than Compass Therapeutics. MannKind is trading at a lower price-to-earnings ratio than Compass Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compass Therapeutics	N/A	N/A	-$66.49M	-$0.40	N/A
MannKind	$348.97M	3.74	$5.86M	-$0.13	N/A

68.4% of Compass Therapeutics shares are held by institutional investors. Comparatively, 49.6% of MannKind shares are held by institutional investors. 18.7% of Compass Therapeutics shares are held by insiders. Comparatively, 2.6% of MannKind shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Compass Therapeutics has a beta of 0.92, indicating that its share price is 8% less volatile than the broader market. Comparatively, MannKind has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market.

Summary

Compass Therapeutics and MannKind tied by winning 8 of the 16 factors compared between the two stocks.

How does Compass Therapeutics compare to Inhibrx Biosciences?

Inhibrx Biosciences (NASDAQ:INBX) and Compass Therapeutics (NASDAQ:CMPX) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, institutional ownership, analyst recommendations, profitability and media sentiment.

Inhibrx Biosciences has a beta of 3.51, meaning that its stock price is 251% more volatile than the broader market. Comparatively, Compass Therapeutics has a beta of 0.92, meaning that its stock price is 8% less volatile than the broader market.

In the previous week, Compass Therapeutics had 14 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 16 mentions for Compass Therapeutics and 2 mentions for Inhibrx Biosciences. Inhibrx Biosciences' average media sentiment score of 0.30 beat Compass Therapeutics' score of 0.05 indicating that Inhibrx Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inhibrx Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Compass Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Compass Therapeutics' return on equity of -38.71% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibrx Biosciences	N/A	-563.90%	-72.32%
Compass Therapeutics	N/A	-38.71%	-34.72%

Inhibrx Biosciences currently has a consensus target price of $150.00, suggesting a potential upside of 66.75%. Compass Therapeutics has a consensus target price of $11.77, suggesting a potential upside of 441.11%. Given Compass Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Compass Therapeutics is more favorable than Inhibrx Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibrx Biosciences	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33
Compass Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88

82.5% of Inhibrx Biosciences shares are held by institutional investors. Comparatively, 68.4% of Compass Therapeutics shares are held by institutional investors. 18.3% of Inhibrx Biosciences shares are held by company insiders. Comparatively, 18.7% of Compass Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Compass Therapeutics has lower revenue, but higher earnings than Inhibrx Biosciences. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than Compass Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibrx Biosciences	$1.30M	1,015.10	-$140.05M	-$8.39	N/A
Compass Therapeutics	N/A	N/A	-$66.49M	-$0.40	N/A

Summary

Compass Therapeutics beats Inhibrx Biosciences on 10 of the 14 factors compared between the two stocks.

Get Compass Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CMPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CMPX vs. The Competition

Export

Metric	Compass Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$391.51M	$3.69B	$7.00B	$12.99B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-5.44	9.02	270.57	25.05
Price / Sales	N/A	1,291.29	659.56	107.93
Price / Cash	N/A	44.95	28.89	37.44
Price / Book	1.96	17.52	11.20	6.43
Net Income	-$66.49M	-$13.25M	$3.45B	$348.10M
7 Day Performance	15.38%	5.02%	3.39%	2.66%
1 Month Performance	-6.65%	-2.12%	-0.72%	-0.85%
1 Year Performance	-19.44%	61.49%	77.42%	23.96%

Compass Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CMPX Compass Therapeutics	2.1639 of 5 stars	$2.18 +1.2%	$11.77 +441.1%	-20.4%	$391.51M	N/A	N/A	20	News Coverage Earnings Report Analyst Forecast Analyst Revision Gap Up
MLTX MoonLake Immunotherapeutics	3.5688 of 5 stars	$17.40 -5.6%	$24.21 +39.2%	-65.2%	$1.36B	N/A	N/A	2	News Coverage Earnings Report
ALVO Alvotech	3.6103 of 5 stars	$3.79 -8.0%	$7.60 +100.5%	-55.0%	$1.24B	$588.90M	N/A	1,460	Positive News
ABSI Absci	2.6115 of 5 stars	$7.93 +1.9%	$13.43 +69.3%	+214.4%	$1.21B	$2.80M	N/A	210	Negative News Upcoming Earnings
MNKD MannKind	2.6019 of 5 stars	$3.80 -2.8%	$9.34 +145.9%	+16.8%	$1.21B	$348.97M	N/A	400	Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CMPX) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compass Therapeutics (CMPX) Competitors

CMPX vs. MLTX, ALVO, ABSI, MNKD, and INBX

How does Compass Therapeutics compare to MoonLake Immunotherapeutics?

Summary

How does Compass Therapeutics compare to Alvotech?

Summary

How does Compass Therapeutics compare to Absci?

Summary

How does Compass Therapeutics compare to MannKind?

Summary

How does Compass Therapeutics compare to Inhibrx Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMPX vs. The Competition

Compass Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compass Therapeutics (CMPX) Competitors

CMPX vs. MLTX, ALVO, ABSI, MNKD, and INBX

How does Compass Therapeutics compare to MoonLake Immunotherapeutics?

Do analysts prefer MLTX or CMPX?

Is MLTX or CMPX more profitable?

Which has better earnings and valuation, MLTX or CMPX?

Which has more risk & volatility, MLTX or CMPX?

Does the media prefer MLTX or CMPX?

Do institutionals & insiders hold more shares of MLTX or CMPX?

Summary

How does Compass Therapeutics compare to Alvotech?

Is CMPX or ALVO more profitable?

Do analysts recommend CMPX or ALVO?

Do institutionals & insiders have more ownership in CMPX or ALVO?

Does the media favor CMPX or ALVO?

Which has better valuation & earnings, CMPX or ALVO?

Which has more volatility & risk, CMPX or ALVO?

Summary

How does Compass Therapeutics compare to Absci?

Is ABSI or CMPX more profitable?

Does the media refer more to ABSI or CMPX?

Which has higher earnings & valuation, ABSI or CMPX?

Do insiders and institutionals believe in ABSI or CMPX?

Which has more volatility and risk, ABSI or CMPX?

Do analysts prefer ABSI or CMPX?

Summary

How does Compass Therapeutics compare to MannKind?

Do analysts prefer CMPX or MNKD?

Is CMPX or MNKD more profitable?

Does the media favor CMPX or MNKD?

Which has higher valuation and earnings, CMPX or MNKD?

Do institutionals and insiders believe in CMPX or MNKD?

Which has more risk and volatility, CMPX or MNKD?

Summary

How does Compass Therapeutics compare to Inhibrx Biosciences?

Which has more volatility and risk, INBX or CMPX?

Does the media prefer INBX or CMPX?

Is INBX or CMPX more profitable?

Do analysts recommend INBX or CMPX?

Do insiders & institutionals hold more shares of INBX or CMPX?

Which has better earnings and valuation, INBX or CMPX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMPX vs. The Competition

Compass Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools